Covalent dual-functional inhibitors of peanut allergies

WO2026064539A1PCT designated stage Publication Date: 2026-03-26UNIV OF NOTRE DAME DU LAC +7
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-09-18
Publication Date
2026-03-26

AI Technical Summary

Technical Problem

Current treatments for peanut allergies, such as antihistamines, mast cell stabilizers, steroids, and anti-IgE antibodies, are ineffective in preventing degranulation responses and can be costly or risky, especially for highly allergic individuals, and existing preventative therapies are time-consuming or trigger anaphylactic reactions.

Method used

Development of covalent dual-functional inhibitors (cMI) that target specific peanut allergens by blocking IgE antibody pathways, using a targeting moiety with a reactive functional group to form a site-directed covalent bond with lysine amino acids, inhibiting mast cell degranulation and reducing allergic reactions.

Benefits of technology

The cMI inhibitors effectively prevent and mitigate peanut allergen-induced degranulation in vitro and in vivo, offering prophylactic and post-exposure treatment options, including use with EpiPen, and are safe for highly allergic individuals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025047017_26032026_PF_FP_ABST
    Figure US2025047017_26032026_PF_FP_ABST
Patent Text Reader

Abstract

The disclosure provides for covalent dual-functional inhibitors of peanut allergic reactions where the inhibitors include a targeting moiety comprising a peanut allergen protein epitope or mimotope peptide sequence, a reactive functional group capable of forming a site-directed covalent bond to the amine moiety of a lysine amino acid of an allergen reactive immunoglobulin, and a variable length spacer comprising oligomers of ethylene glycol monomers, amino acids, saccharides, hydrocarbons, fluorinated hydrocarbons, or a combination thereof, wherein the spacer is conjugated by one or more amide bonds to the TM and the FG.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Covalent heterobivalent antibody inhibitors and ligands

    US20210115157A1

  • Nanoallergens and uses thereof

    US20210138089A1

  • Peanut allergy epitope

    WO2023060151A1